Legal & General Group
ORKA

Legal & General Group’s Oruka Therapeutics ORKA Stock Holding History

Legal & General Group’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.87M Buy
30,198
+14,280
+90% +$951K ﹤0.01% 1822
2026
Q1 		$781K Sell
15,918
-2,826
-15% -$98.2K ﹤0.01% 2217
2025
Q4 		$568K Buy
18,744
+16,267
+657% +$453K ﹤0.01% 2389
2025
Q3 		$47.6K Hold
2,477
– – ﹤0.01% 2744
2025
Q2 		$27.8K Buy
+2,477
New +$25.8K ﹤0.01% 2880

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Legal & General Group's ORKA Position: Q2 2026 in Review

Legal & General Group increased its Oruka Therapeutics (ORKA) stake by 90% in Q2 2026, buying an estimated $951K and bringing the position to 30,198 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1822.

Legal & General Group first reported a position in ORKA in Q2 2025 and has held it in 5 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Legal & General Group held 30,198 shares of Oruka Therapeutics worth $2.87M as of Q2 2026.
  • Legal & General Group bought 14,280 Oruka Therapeutics shares in Q2 2026, an estimated $951K.
  • Oruka Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1822 holding.
  • Legal & General Group first reported a position in Oruka Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.